Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
Nassar A, Kim S, Aredo J, Feng J, Shepherd F, Xu C, Kaldas D, Gray J, Dilling T, Neal J, Wakelee H, Liu Y, Lin S, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron T, Thummalapalli R, Yu H, Owen D, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris J, Nagasaka M, Ayanambakkam A, Velazquez A, Ragavan M, Lin J, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar S, Gupta S, Leal T, Kwiatkowski D, Mak R, Adib E, Naqash A, Goldberg S. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. Journal Of Thoracic Oncology 2024, 19: 928-940. PMID: 38278303, DOI: 10.1016/j.jtho.2024.01.012.Peer-Reviewed Original ResearchTreatment-related adverse eventsConcurrent chemoradiationConsolidation therapyConsolidation durvalumabOverall survivalEGFR-mutant non-small-cell lung cancerAny-grade TRAEsCommon Terminology Criteria for Adverse Events versionFollow-upReal-world progression-free survivalObservational cohortNon-small-cell lung cancerPatients treated with osimertinibEGFR tyrosine kinase inhibitorsMedian duration of treatmentMulticenter retrospective cohort studyMultivariate Cox regression analysisDefinitive concurrent chemoradiationInternational retrospective analysisOptimal consolidation therapySensitive EGFR mutationsTreated with durvalumabAdverse Events versionProgression-free survivalStage III NSCLC
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply